
Home » Novavax Acquires Praha Vaccines to Expand COVID-19 Manufacturing Capacity
Novavax Acquires Praha Vaccines to Expand COVID-19 Manufacturing Capacity

Novavax is expanding its manufacturing capacity for its COVID-19 vaccine candidate by acquiring a manufacturer in the Czech Republic.
The $167 million acquisition of Praha Vaccines is expected to provide an annual capacity of more than 1 billion doses of antigen for Novavax’s vaccine candidate starting in 2021.
Praha Vaccines is part of the India-based Poonawalla Group that includes the Serum Institute of India, a manufacturer of pediatric vaccines.
Upcoming Events
-
01Feb
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb